Drug Trial Radar · NCT06281470
The Safety and Tolerability of WS016 in Healthy Chinese Volunteers
Last checked: Nov 19, 2026Latest source record: Feb 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
66
Actual
Start
Feb 13, 2023
Primary completion
Jun 15, 2023
Study completion Jun 15, 2023
Sponsor
- Lead sponsor
- Waterstone Pharmaceutical (Wuhan) Co., LTD.Industry
- Sponsor type
- Industry
- First posted
- Feb 28, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This clinic trial evaluates the safety and tolerability of single- and multiple- ascending doses of WS016 in healthy adult participants. There will be about 64 participants,48 active and 16 placebo.
Conditions
- Hyperkalemia
Interventions
WS016 Single Dose(6g)Drug
WS016 6g, to be administered orally as a single dose.
WS016 Single Dose(12g)Drug
WS016 12g, to be administered orally as a single dose.
WS016 Single Dose(24g)Drug
WS016 24g, to be administered orally as a single dose.
WS016 Single Dose(36g)Drug
WS016 36g, to be administered orally as a single dose.
WS016 Single Dose(48g)Drug
WS016 48g, to be administered orally as a single dose.
SAD matching placeboDrug
Matching placebo, to be administered orally as a single dose.
WS016 Multiple Dose(12g)Drug
WS016 12g, to be administered orally once daily for a consecutive period of 7 days.
WS016 Multiple Dose(24g)Drug
WS016 24g, to be administered orally once daily for a consecutive period of 7 days.
WS016 Multiple Dose(48g)Drug
WS016 48g, to be administered orally once daily for a consecutive period of 7 days.
MAD matching placeboDrug
Matching placebo, to be administered orally once daily for a consecutive period of 7 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants that experience Adverse Events (AEs) and Serious Adverse Events (SAEs) after single- and multiple- ascending doseTime frame: up to Day 17
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zhejiang Xiaoshan Hospital
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.